The AI Supremacy: Analyzing the Massive Wave of Venture Capital Megadeals

In a week that underscored the relentless dominance of artificial intelligence in the global venture capital ecosystem, U.S.-based startups once again secured billions in capital, proving that investor appetite for transformative technology remains insatiable. The latest data reveals a landscape where “megadeals”—rounds exceeding $100 million—are becoming the standard for promising startups rather than the exception.

While AI remains the clear frontrunner in attracting massive capital injections, the diversification into secondary sectors like biotech, defense technology, and digital infrastructure highlights a maturing market that is betting heavily on the long-term utility of these platforms.

The Main Facts: A $1.5 Billion Headline

The centerpiece of this week’s funding activity is the staggering $1.5 billion Series F round raised by Baseten, an AI inference technology provider. This transaction, which has propelled the San Francisco-based firm to a $13 billion valuation, is not just a testament to the company’s growth but also a marker of the speed at which the industry is moving. Having completed four distinct fundraises in just 18 months, Baseten has effectively become a bellwether for the infrastructure layer of the AI boom.

Close behind in the spotlight is AppsFlyer, which secured $1 billion to bolster its digital marketing analytics platform. The involvement of tech giants like Meta, Google, and Unity in this round signals that the world’s largest digital platforms are eager to align themselves with the tools that define modern data attribution and marketing efficacy.

Chronology of Capital: A Breakdown of the Top 10

The following list details the most significant U.S.-based funding events reported between June 18 and June 26, reflecting the intensity of current market activity.

1. Baseten ($1.5 Billion, Series F)

As a provider of critical systems software for running AI workloads, Baseten’s latest influx of capital—co-led by Altimeter Capital, Conviction Partners, Spark Capital, Sands Capital, and Wellington Management—solidifies its position as an essential pillar of the AI tech stack.

2. AppsFlyer ($1 Billion, Series E)

AppsFlyer’s $1 billion raise, resulting in a $2.7 billion post-money valuation, highlights the sustained demand for sophisticated marketing intelligence in an increasingly complex digital privacy landscape.

3. Groq ($650 Million)

Despite a turbulent period involving the migration of key staff to Nvidia, Groq successfully raised $650 million. The company, led by Infinitum and Disruptive, remains a focal point for investors betting on specialized AI inference infrastructure.

4. Ollin Biosciences ($330 Million, Series B)

Representing the biotech sector, Austin-based Ollin Biosciences secured $330 million to advance its ophthalmic therapy pipeline. Led by TCG Crossover and Arch Venture Partners, the deal emphasizes that investors are still finding significant value in targeted medical innovation.

5. General Intuition ($320 Million, Series A)

Foundational AI continues to draw massive attention. New York-based General Intuition, which develops AI models rooted in complex gameplay simulations, reached a $2.3 billion valuation with support from Khosla Ventures, Jeff Bezos, and General Catalyst.

6. Peregrine Technologies ($250 Million, Series D)

Government software is seeing a resurgence. Peregrine’s $250 million round, which values the company at $6.8 billion, underscores the growing reliance of public safety agencies on sophisticated data platforms.

7. Quantifind ($200 Million, Growth)

Palo Alto’s Quantifind, specializing in financial crime detection and risk intelligence for national security, secured $200 million in growth capital led by Summit Partners.

8. Mirendil ($200 Million, Seed)

In a rare and massive seed round, Mirendil secured $200 million. Backed by heavyweights Andreessen Horowitz, Kleiner Perkins, and Nvidia, the company is positioning itself as a frontier laboratory for AI R&D.

9. Upscale AI ($190 Million, Series A Extension)

Continuing the trend of infrastructure investment, Upscale AI raised an extension that brings its total funding to $500 million, securing a $2 billion valuation.

10. Osanni Bio ($190 Million, Series B)

Closing out the top ten, Osanni Bio’s $190 million round confirms the robust nature of the biotech funding environment, with Patient Square Capital leading the charge.

Supporting Data: The Global Context

The venture capital surge was not limited to the United States. International markets, particularly in Europe, demonstrated significant momentum. Berlin-based defense tech firm Stark reportedly raised $569 million, while Paris-based insurance startup Alan secured $460 million in primary and secondary equity.

These figures suggest that while the U.S. remains the primary engine for AI innovation, the geopolitical shift toward sovereign defense technology and the modernization of traditional insurance sectors is a global phenomenon. The concentration of capital in these regions reflects a synchronized effort to build the next generation of "sovereign" technology companies.

Official Responses and Strategic Shifts

While many of these companies have maintained a low profile regarding their long-term roadmaps, the strategic composition of their investors tells a clear story. The presence of Nvidia in both Groq’s and Mirendil’s cap tables suggests a strategic "hub-and-spoke" model where the chip giant is effectively hedging its bets across the entire AI inference ecosystem.

Similarly, the involvement of Meta and Google in the AppsFlyer round points toward a collaborative—if competitive—effort to ensure that marketing data remains actionable in a post-cookie digital world. For founders, these rounds represent more than just cash; they represent an "insurance policy" provided by the largest incumbents in the tech industry to ensure these startups do not fail.

Implications: What This Means for the Future

The implications of this week’s activity are threefold:

1. The Consolidation of the AI Stack

We are witnessing the "platformization" of AI. Companies like Baseten and Groq are not just building software; they are building the plumbing for the future of the internet. By securing billions, they are effectively locking in the market share required to become the standard infrastructure providers for the next decade.

2. The Return of Biotech as a "Safe Haven"

Whenever AI volatility threatens the market, biotech emerges as the preferred secondary hedge. The success of Ollin Biosciences and Osanni Bio suggests that investors view the long-term, high-barrier-to-entry nature of drug development as a necessary counterbalance to the high-velocity, high-risk nature of software-based AI.

3. Valuation Inflation or Value Realization?

With many of these companies reaching multi-billion dollar valuations on the back of Series A or B rounds, critics may point to a bubble. However, the consistent participation of Tier-1 venture firms and strategic corporate partners indicates that this capital is being deployed with a specific outcome in mind: the rapid scale-up of operational capabilities.

Conclusion: A High-Stakes Environment

The current funding environment is characterized by a "winner-take-all" mentality. Companies that can demonstrate a clear path to infrastructure dominance or critical medical breakthroughs are finding no shortage of capital. However, the sheer size of these rounds creates a massive burden of proof. As we move through 2026, the market will inevitably pivot from asking, "How much capital did you raise?" to "What is your revenue-to-valuation multiple?"

For now, the momentum remains firmly in favor of the founders. Whether this current spree of megadeals leads to sustainable industry giants or a cooling period of consolidation remains the most significant question in the venture landscape today. Stay tuned to the Crunchbase Megadeals Board for real-time updates as these companies deploy their capital and redefine their respective industries.